Analyst Ratings for Moderna
Portfolio Pulse from Benzinga Insights
In the last quarter, Moderna (NASDAQ:MRNA) received 1 bullish rating, 3 indifferent ratings, and no bearish ratings from analysts. The company's average 12-month price target is $167.25, down 1.33% from the previous average of $169.50.
June 26, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Moderna has an average 12-month price target of $167.25, with 1 bullish and 3 indifferent analyst ratings in the last quarter.
The mixed analyst ratings for Moderna indicate a neutral short-term impact on the stock price. The average 12-month price target has decreased slightly, but there are no bearish ratings, suggesting that the overall sentiment is not negative.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100